MTNR1A-based melatonin-inducible gene switch

This engineered switch converts melatonin sensing through ectopic MTNR1A into CREB-driven transgene expression from a synthetic promoter. The abstract states that it responds within the physiological melatonin range and preferentially to night-phase levels.

The system requires ectopic MTNR1A expression, an amplifier module using the native Gαs signaling cascade, and a synthetic promoter controlling the transgene. In the proof-of-concept application, engineered cells were encapsulated in alginate and implanted in mice.

It provides a way to link endogenous circadian biomarkers or licensed melatonin-receptor agonists to timed therapeutic protein release. This addresses the need for temporally regulated outputs compatible with once-daily treatment logic.

The abstract does not show broad validation across multiple disease settings or delivery formats. It also does not specify exact construct details or all agonists tested.

The source says the authors explored human receptors responsive to oscillatory molecules and identified MTNR1A as the promising sensor, implying other receptor options were considered upstream. No alternative named switch platform is explicitly described in the abstract.